tbuckley/cabot-search huggingface dataset:
Donor Age is an Independent Risk Factor for Calcineurin Inhibitor-Induced Neurotoxicity after Liver Transplantation
Authors: E. Martinez, A. Lué, M. Navarro, G. Garcia, M.J. Domper, S. Lorente, J.J. Araiz, F.A. Garcia-Gil, M.T. Serrano
Journal: Journal of Hepatology (2016)
Molecular analysis of the randomized phase II/III study of the anti-IGF-1R antibody dalotuzumab (MK-0646) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory KRAS wild-type metastatic colorectal cancer (mCRC).
Authors: David J. Watkins, Mark Ayers, David Cunningham, Josep Tabernero, Sabine Tejpar, Tae-You Kim, Tae Won Kim, Sun Young Kim, Jae Kyung Roh, Philip James Beale, Young Suk Park, Tormod Kyrre Guren, Andrey Loboda, Michael Nebozhyn, Robin Mogg, Jared Lunceford, Emmett V. Schmidt, Holly M. Brown, Sriram Sathyanarayanan, David J. Mauro
Journal: Journal of Clinical Oncology (2012)

3531 Background: Previously reported results of this randomized study demonstrated that the addition of dalotuzumab (Dz) worsened the PFS and OS of chemofractory mCRC patients receiving Cx and Ir (Watkins et al; ASCO 2011). Comprehensive molecular analysis has been undertaken retrospectively to identify possible predictors of Cx resistance and Dz response. Methods: Quantitative RT-PCR for IGF-1, IGF-2, immunohistochemistry for IGF-1R and microarray expression profiling was conducted on archival tumor tissue. All patients had received Cx and Ir with either placebo (n=107), weekly Dz (n=112), or 2 weekly Dz (n=110). Results: Data from 292 and 206 patients was successfully obtained by RT-PCR or microarray respectively. Within the placebo arm, high IGF-1 expression was found to be associated with resistance to Cx (IGF-1-/IGF-1+; PFS 6.7/3.7 months, OS 15.5/9.6 months). High IGF-1 expression was associated with benefit from the addition of weekly Dz (placebo/weekly Dz; PFS 3.7/5.7 months, OS 9.6/18.2 months). By contrast the addition of Dz was not effective in tumors with high IGF-2 expression (placebo/weekly Dz; PFS 8.4/2.7 months). Microarray analysis revealed distinct populations that differentially correlated with Cx and Dz response. An epithelial phenotype appeared more associated with Cx response, whereas a mesenchymal phenotype more associated with Dz response. Rectal cancers showed greater association with increased IGF-1 expression, EMT gene signature and Dz response. Conclusions: These data support IGF-1 and IGF-2 as potential biomarkers for response to Dz therapy and high IGF-1 as a marker of resistance to Cx therapy. Based on these data Dz is being further evaluated in a molecularly selected population of mCRC. [Table: see text]
Antiviral Efficacy and Host Immune Response Induction with SB 9200, an Oral Prodrug of the Dinucleotide SB 9000, in Combination with Entecavir in the Woodchuck Model of Chronic Hepatitis B
Authors: K. Korolowicz, M. Balarezo, R. Iyer, S. Padmanabhan, D. Cleary, R. Gimi, A. Sheri, M. Suresh, C. Yon, R. Tucker, N. Afdhal, S. Menne
Journal: Journal of Hepatology (2016)
Prediction of Hepatocellular Carcinoma Recurrence after Radiofrequency Ablation using Liver Stiffness Measurement (Fibroscan)
Authors: Y.R. Lee, S.Y. Park, S.U. Kim, S.K. Jang, S. Lee, S.Y. Jang, W.Y. Tak, Y.O. Kweon, J.G. Park
Journal: Journal of Hepatology (2016)
Baseline Low Liver Stiffness Value can Predict a Favorable Regression of Fibrosis after 5 Years of Antiviral Therapy in Patients with Chronic Hepatitis B
Authors: Y.E. Chon, M.S. Min, K.S. Jung, K.-H. Han, B.K. Kim, S.U. Kim, D.Y. Kim, S.H. Ahn, J.Y. Park
Journal: Journal of Hepatology (2016)
Predicting Short and Long-Term Mortality of Hospitalized Portuguese Patients with Alcoholic Hepatitis
Authors: S.R. Fernandes, P.M. Costa, S. Vitor, P. Santos, C.M. Moura, J.R. Carvalho, H. Cortez-Pinto, F. Ramalho, J. Velosa
Journal: Journal of Hepatology (2016)
P0879 : Examining the clinical course of genotype 1 chronic Hepatitis C patients treated with the COSMOS regimen: including patients with advanced liver disease, and East Asian ancestry
Authors: M. Roytman, R. Ramkissoon, L. Hong, R. Trujillo, L. Huddleston, P. Poerzgen, T. Seto, N. Tsai
Journal: Journal of Hepatology (2015)
CNTO 328, a Monoclonal Antibody to Interleukin-6, Is Active as a Single Agent in Castleman’s Disease: Preliminary Results of a Phase I Study.
Authors: Frits Van Rhee, Luis Fayad, Peter Voorhees, Richard R Furman, Hossein Borghaei, Sagar Lonial, Lubomir Sokol, Julie Crawford, Mark Cornfeld, Ming Qi, Jennifer Herring, Xiang Qin, Razelle Kurzrock
Journal: Blood (2008)
Adipose Tissue-Liver Axis: Involvement of the TH17 Pathway in the Progression of Human NAFLD
Authors: C.M. Chackelevicius, P.J. Giraudi, S.E. Gambaro, S. Palmisano, M. Giuricin, N. de Manzini, D. Bonazza, F. Zanconati, C. Tiribelli, N. Rosso
Journal: Journal of Hepatology (2016)
Prevalence and Characterization of NS5A Resistance Associated Variants in Patients who Relapsed following Exposure to NS5A Inhibitors
Authors: P. Halfon, C. Scholtès, S. Mohamed, G. Penaranda, V. Leroy, M. Bourlière, D. Ouzan, L. Polverel, M.-A. Thélu, F. Zoulim, H. Khiri, S. Larrat
Journal: Journal of Hepatology (2016)
Methylation Patterns in Patients with High-Risk Myelodysplatic Syndromes and Secondary Acute Myeloid Leukemia Treated with Azacitidine (high-risk MDS 2009 protocol from CETLAM Group)
Authors: Marta Cabezón, Yulia Medvedeva, Joan Bargay, Blanca Xicoy, Sílvia Marcé, Ramon Guàrdia, Salut Brunet, Carmen Pedro, Mar Tormo, Victor Marco, Lourdes Escoda, Llorenç Font, Elena Rámila, David Valcárcel, Josep Maria Martí, Josep Borras, Evarist Feliu, Fuensanta Millá, Tanya Vavouri, Lurdes Zamora
Journal: Blood (2015)
Bone alkaline phosphatase doubling time and outcome in metastatic hormone-refractory prostate cancer patients
Authors: D. J. Sleep, S. M. Hulting, J. D. Isaacson, A. R. Allen
Journal: Journal of Clinical Oncology (2004)

4621 Background: Bone alkaline phosphatase (BAP) has been validated as a potential predictor of survival in hormone-refractory prostate cancer (HRPC) patients. Phase 2 results indicate that atrasentan, a potent, selective, oral endothelin A receptor antagonist, significantly attenuates BAP rise in HRPC patients. We tested the hypothesis that BAP response to treatment is predictive of time to disease progression (TTP) and survival. Methods: Data from a randomized, double-blind, placebo-controlled phase 3 trial of HRPC patients given either placebo or atrasentan 10 mg QD were combined. Values from 681 patients with at least 3 BAP values on treatment were analyzed. Data from treatment arms were pooled and stratified by the time over which BAP doubled (BAPDT) <12 mo vs ≥12 mo. Kaplan-Meier methodology was used to compare TTP (a composite of radiographic and clinical measures) and survival between the BAPDT <12 mo and ≥12 mo groups. In addition, frequency tables from the pooled data based on quartiles of time to BAP progression (TTBAP, ≥50% increase from nadir BAP value) vs quartiles of survival and TTP were analyzed, excluding subjects censored for both survival/TTP and TTBAP events. Results: 304 patients had BAPDT <12 mo; 377 had BAPDT ≥12 mo. Patients with BAPDT ≥12 mo had a significantly longer median TTP and a significantly longer time to death than those with BAPDT <12 mo (table). Frequency tables of TTBAP vs TTP and TTBAP vs survival also indicate that early TTBAP was associated with a faster TTP and a shorter survival duration. Conclusions: These data show that a BAPDT <12 mo is predictive of early disease progression and reduced survival of HRPC patients, independent of therapy. This association warrants further exploration to determine whether BAP kinetics is a suitable surrogate endpoint for disease progression or survival. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Abbott Laboratories Abbott Laboratories
Simeprevir plus Sofosbuvir for Hepatitis C Virus Genotype 4 Infection: A Phase 3, Open-Label Study
Authors: M. Buti, J.L. Calleja, X. Forns, M. Diago, E. Ortega, J. Crespo, R. Planas, B. Fevery, D. Kurland, A. Buelens, C. Corbett, R. Kalmeijer, W. Jessner
Journal: Journal of Hepatology (2016)
Interobserver Reproducibility of a 2D- Shear Wave Elastography (2D-SWE) Technique and the Impact of Ultrasound Experience in Achivieng Reliable Data
Authors: T.V. Moga, A.M. Stepan, C. Pienar, A. Popescu, R. Sirli, M. Danila, I. Sporea
Journal: Journal of Hepatology (2016)
Prediction of Post-Operative Liver Failure in Cirrhotics Undergoing Surgical Resection for Hepatocellular Carcinoma: The Role of Liver Stiffness Measured by Acoustic Radiation Force Impulse andthe Proposal for a New Mathematical Model Score
Authors: C. Iegri, A. De Santis, G. Grazi, M. Rossi, M. Lupo, G. Gallusi, M. Forlino, S. Di Filippo, F. Melandro
Journal: Journal of Hepatology (2016)
Efficacy of Prolonged Tenofovir Monotherapy for Partial Virologic Response to Tenofovir in Treatment-Naïve Chronic Hepatitis B Patients
Authors: B.S. Kim, M.K. Kim, S.M. Kang, S.H. Kim, J.E. Song, G.Y. Kim, S.A. Baek, C.H. Lee
Journal: Journal of Hepatology (2016)
Abstract 099: Exercise-Induced Cardioprotection Against Ischemia-Reperfusion Injury Is Abolished by Opioid System Blockage Using an In Vitro Rat Model
Authors: Juliana P Borges, Lorena S Paes, Eduardo V Tibiriçá, Marcos A Lessa
Journal: Circulation Research (2013)

Introduction: A single exercise session releases opioid peptides considered to be associated to cardioprotection. However, the link between exercise-induced cardioprotection and the opioid system remains unclear. Therefore, the study aims to investigate the involvement of opioid receptors in exercise-induced cardioprotection in rats submitted to myocardial injury by ischemia/reperfusion (I/R) in vitro . Methods: Male Wistar rats (250-300g) were randomly divided into 3 groups submitted to I/R: control (CTR; n=5), exercised (EX; n=5) and exercised treated by naloxone, a non-selective opioid receptor antagonist (EX+NAL; n=5). The exercised groups underwent 4 consecutive days of treadmill training (60 min at 70% of maximal oxygen consumption). After the last exercise session (24h), the hearts were removed and immediately installed on a modified Langendorff apparatus. A latex balloon was inserted in the left ventricle (LV) to monitor the LV developed pressure (%LVDP). All hearts underwent a period of 30 min of sustained global ischemia followed by 1 h of reperfusion. After reperfusion, LV was sliced and incubated 20 min in triphenyltetrazolium to measure infarct size. Results: Anova two-way showed that CTR group presented a larger infarct area when compared to EXE group (32.9±9.2% vs 11.3±4.0% respectively; p&lt;0.05). Naloxone treatment completely blocked the exercise-induced cardioprotection (28.1±8.0%). In respect to %LVDP, CTR and EXE+NAL showed significantly lower results compared to EXE group from 25 min of reperfusion. Conclusions: Our results indicate that opioid system is involved, at least in part, in cardioprotective effects of aerobic exercise in rats.
In-Hospital Mortality Related to Hepatic Encephalopathy is Independent of Acute-On-Chronic Liver Failure and Varies Significantly across North America: Nacseld Experience
Authors: J.S. Bajaj, K. Reddy, P. Tandon, G. Garcia-Tsao, F. Wong, P. Kamath, S. Biggins, M. Fallon, B. Maliakkal, P. Thuluvath, R. Subramanian, H. Vargas, J. Lai, L. Thacker, J. O’leary
Journal: Journal of Hepatology (2016)
Proteomic Analysis Identifies Outcome-Predictive Clusters in Patients with Peripheral T-Cell Lymphoma, Not Otherwise Specified
Authors: Maja Ludvigsen, Martin Bjerregaard Pedersen, Stephen Jacques Hamilton-Dutoit, Knud Bendix, Michael Boe Møller, Peter H. Nørgaard, Tim Svenstrup Poulsen, Søren Besenbacher, Francesco d'Amore, Bent Honoré
Journal: Blood (2014)
Influence of pretreatment of piperazine ferulate on pharmacokinetic parameters of methotrexate in methotrexate-induced renal injury model rats by HPLC-MS
Authors: Huiyan Shi, Chenzhi Hou, Liqiang Gu, Zhe Wei, Hang Xing, Meiyu Zhang, Shixiao Wang, Longshan Zhao, Kaishun Bi, Xiaohui Chen
Journal: Asian Journal of Pharmaceutical Sciences (2016)

The present study was designed to investigate the influence of the pretreatment of piperazine ferulate on pharmacokinetic parameters of methotrexate in methotrexate-induced renal injury rats. A simple and efficient high performance liquid chromatography coupled with mass spectrometry (HPLC-MS) method was developed to determine methotrexate in rat plasma. Methotrexate and syringic acid (internal standard) were extracted from rat plasma samples by protein precipitation with acetonitrile. The analysis was performed on a CAPCELL PAK C18 column (150 mm × 4.6 mm, 5 µm) with acetonitrile and 5 mmol/l ammonium acetate aqueous (10:90, v/v). The linear range was 5.0 × 10-2 to 100.0 µg/ml for methotrexate. Other parameters were all within the acceptance criteria. The validated method was successfully applied the pharmacokinetic study of methotrexate between two methotrexate treated groups (with and without the pretreatment of piperazine ferulate). Compared with the methotrexate treated alone group, the pharmacokinetic parameters in the methotrexate with the pretreatment of piperazine ferulate group showed significantly lower MRT(0-t), MRT(0-∞) and T1/2. Results suggested that methotrexate can be rapidly eliminated, cleared or metabolized in rat blood, which might be related to the pretreatment of piperazine ferulate. The method provided deeper insights into rational clinical use of methotrexate with the pretreatment of piperazine ferulate on cancer patients with renal dysfunction.
Stard1 Depletion Protects against Valproic Acid-Induced Sensitization to Acetaminophen Hepatotoxicity
Authors: A. Baulies, S. Torres, C. Alarcón-Vila, E. Solsona, D. Robles, V. Ribas, C. García-Ruiz, J.C. Fernández-Checa
Journal: Journal of Hepatology (2016)
An Immunological Biomarker to Predict Hepatic Flares upon Nuc Therapy Discontinuation in Chronic Hepatitis B
Authors: L. Rivino, N. Le Bert, U. Gill, Y. Cheng, K. Kunasegaran, D. Tan, S. Koh, N. Hansi, G. Foster, E. Newell, P. Kennedy, A. Bertoletti
Journal: Journal of Hepatology (2016)
KIR3DL1 in Combination with HLA-BW4-80T is Associated with Superior Functionality of NK Cells and Spontaneous Immune Control of HCV Infection in People who Inject Drugs
Authors: C. Thoens, T. Senff, T.J. Hydes, F.M. Heinemann, A. Heinold, M. Heilmann, M. Uhrberg, N. Scherbaum, S. Khakoo, J. Timm
Journal: Journal of Hepatology (2016)
Phase I Trial of IL-21 Ex Vivo Expanded NK Cells Administration to Prevent Disease Relapse after Haploidentical Stem-Cell Transplantation for Myeloid Leukemias
Authors: Stefan O. Ciurea, Dean A. Lee, Kai Cao, Gabriela Rondon, Julianne Chen, Dana B. Willis, Sairah Ahmed, Eric Yvon, Katayoun Rezvani, Elizabeth J. Shpall, Richard E. Champlin
Journal: Blood (2015)
Injectable Diabetes Drug Approved
Authors: Rebecca Voelker
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Is Genome Complexity a Consequence of Inefficient Selection? Evidence from Intron Creation in Nonrecombining Regions
Authors: Scott W Roy
Journal: Molecular Biology and Evolution (2016)

Genomes show remarkable variation in architecture and complexity across organisms, with large differences in genome size and in numbers of genes, gene duplicates, introns and transposable elements. These differences have important implications for transcriptome and regulatory complexity and ultimately for organismal complexity. Numbers of spliceosomal introns show particularly striking differences, ranging across organisms from zero to hundreds of thousands of introns per genome. The causes of these differences remain poorly understood. According to one influential perspective, differences across species reflect the differential ability of selection in different populations to eliminate allegedly deleterious intron-containing alleles. Direct tests of this theory have been elusive. Here, I study evolution of intron-exon structures in genomic regions of recombination suppression (RRSs), which experience drastically reduced selective efficiency due to hitchhiking and background selection. I studied intron creation in eight independently evolved RRSs, spanning substantial diversity phylogenetically (plants, animals, fungi and brown algae) and biologically (sex chromosomes, mating type chromosomes, genomic regions flanking self-incompatibility loci, and the Drosophila "dot" chromosome). To identify newly created introns in RRSs, I compared intron positions in RRS genes with those in homologous genes. I found very few intron gains: no intron gains were observed in 7/8 studied data sets, and only three intron gains were observed overall (on the Drosophila dot chromosome). These results suggest that efficiency of selection may not be a major cause of differences in intron-exon structures across organisms. Instead, rates of spontaneous intron-creating and intron-deleting mutations may play the central role in shaping intron-exon structures.
Preclinical Characterization of E7438, a Potent, Selective Inhibitor of Protein Methyltransferase EZH2 with Robust Antitumor Activity Against EZH2 Mutated Non-Hodgkin Lymphoma Xenografts in Mice
Authors: Heike Keilhack, Akira Yokoi, Sarah K Knutson, Tim Wigle, Natalie Warholic, Satoshi Kawano, Yukinori Minoshima, Kuan-Chun Huang, Galina Kuznetsov, Namita Kumar, Christine R Klaus, Christina J Allain, Alejandra Raimondi, Margaret Porter Scott, Richard Chesworth, Mikel P Moyer, Toshimitsu Uenaka, Robert A Copeland, Victoria M Richon, Roy M Pollock, Kevin W Kuntz
Journal: Blood (2012)
A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.
Authors: A. M. Traynor, R. Kurzrock, H. H. Bailey, S. Attia, C. Scheffold, B. van Leeuwen, B. Wu, G. S. Falchook, S. L. Moulder, J. Wheler
Journal: Journal of Clinical Oncology (2010)

3078 Background: Upregulation of PI3K pathway signaling is associated with tumor resistance to P and C. The oral selective Class I PI3K inhibitor XL147 potentiates the antitumor efficacy of P and C without exacerbated toxicity in preclinical xenograft tumor models. Methods: A standard 3 + 3 design was used. Pts receive intravenous P/C on day 1 of each 21-day cycle, and oral XL147 qd. Prior P and/or C were permitted. Maximum tolerated dose (MTD) expansion cohorts will include patients with endometrial, ovarian and non-small cell lung cancer. Dose limiting toxicities are determined using cycle 1 safety data. Tumor response is evaluated every 6 weeks. Results: 19 pts with advanced solid tumors (including 5 breast, 2 cervical, and 1 endometrial) have been enrolled. Pts have been treated at 6 dose levels up to 600mg XL147/175mg.m−2 P/AUC 6 C. The MTD has not yet been established. One grade 4 thrombocytopenia assessed as study treatment related was reported. The most frequently reported related AEs were neutropenia and fatigue (each 65%), thrombocytopenia (53%), and anemia (47%). Four pts had a confirmed PR with the following reductions (sum of tumor target lesions): 72% (tongue), 63% (tonsillar), 45% (esophageal), and 42% (cervical). One Merkel cell cancer pt had an unconfirmed PR (47% reduction of a single target lesion). In addition, 12 pts continued on treatment ≥ 12 weeks, with 4 pts ≥ 24 weeks. All PRs occurred in pts who had been previously treated with a platinum-containing regimen. No major PK interaction between XL147 and P/C was evident across cohorts based on comparison with single agent data. Inhibition of PI3K pathway signaling has been demonstrated. For example, post-dose reductions in pAKT-T308 (67%), p4EBP1 (64%), and pERK (73%) were observed at day 49, with an associated reduction in Ki67 (32%) and induction of apoptosis (2.4-fold), in paired tumor biopsies from a colon cancer pt. Conclusions: XL147 at doses up to 600 mg in combination with P at 175 mg.m−2 and C at AUC 6 is generally well tolerated, with no major PK interaction or emergent toxicities, and results in robust pharmacodynamic activity and tumor regression in heavily pretreated pts. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Exelixis Exelixis Exelixis
A Detailed Phenotypic Analysis Using Six Color Flow Cytometry of Lymphocyte Subsets Mobilized with AMD3100 Compared to G-CSF.
Authors: Yoshiyuki Takahashi, S. Chakrabarti, R. Sriniivasan, A. Lundqvist, E.J. Read, H. Khuu, S. Leitman, C. Bolan, A.J. Barrett, G. Calandra, Richard Childs
Journal: Blood (2004)
Applicability, Reliability and Diagnostic Performance of Fibroscan for Liver Evaluation in Severe Obese Patients Candidate to Bariatric Surgery
Authors: C. Barsamian, S. Czernichow, M. Sasso, V. Miette, D. Parlier, J.-L. Bouillot, J.-F. Emile, C. Carette
Journal: Journal of Hepatology (2016)